Medical Therapy. Efficacy or Lack of Efficacy

Congenital Surfactant C Deficiency with Pulmonary Hypertension – A Case Report

Wei Chard Chua, I-Chen Chen, Yi-Ching Liu, Yen-Hsien Wu, Shih-Hsing Lo, Jong-Hau Hsu, Peir-In Liang, Hsiu-Lin Chen, Zen-Kong DaiKaohsiung Medical University Hospital. Taiwan ChildrenChildren 2022; 9: DOI: 10.3390/children9101435 AbstractInterstitial lung diseases in children are a diverse group in terms of etiology and pathogenesis. With advances in genetic testing, mutations in surfactant protein have now been identified […]

Congenital Surfactant C Deficiency with Pulmonary Hypertension – A Case Report Read More »

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom

Andrew Constantine, Robert M. R. Tulloh, Konstantinos Dimopoulos, Petra Jenkins, Robin Condliffe, Katrijn Jansen, Natali A. Y. Chung, James Oliver, Helen Parry, Samantha Fitzsimmons, Niki Walker, Stephen John Wort, Vasilios Papaioannou, Kate von Klemperer, Paul CliftRoyal Brompton HospitalRoyal Brompton and Harefield Hospitals. Imperial College London. Liverpool Heart and Chest Hospital. University Hospital Bristol. Royal Hallamshire

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom Read More »

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn

Sourabh Verma, Rishi Lumba, Sadaf H. Kazmi, Michelle J. Vaz, Shrawani Soorneela Prakash, Sean M. Bailey, Pradeep V. Mally, Tara M. RandisNYU Grossman School of Medicine. University of South Florida. United States American Journal of PerinatologyAm J Perinatol 2022; 39: 1441-1448DOI: 10.1055/s-0040-1722653 AbstractObjective: The study aimed to evaluate the effects of inhaled iloprost on oxygenation indices in

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn Read More »

Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial

Safaa S. Iman, Rania A. El-Farrash, Amr S. Taha, Ghada A. SalehAin Shams University and Cairo Ministry of Health.Egypt Journal of Cardiovascular PharmacologyJ Cardiovasc Pharmacol 2022; 80: 746-752DOI: 10.1097/FJC.0000000000001332 AbstractPersistent pulmonary hypertension of the newborn (PPHN) is a condition caused by failure of pulmonary vascular adaptation at birth, resulting in severe hypoxia. Several therapeutic modalities are

Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial Read More »

A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD

Henry P. Foote, Christoph P. Hornik, Kevin D. Hill, Alexandre T. Rotta, Karan R. Kumar, Elizabeth J. ThompsonDuke University School of MedicineUnited States Cardiology in the YoungCardiol Young 2022; 20: DOI: 10.1017/S1047951122002293 AbstractObjectives: Complications from pulmonary hypertension are one of the leading contributors to morbidity and mortality post-cardiopulmonary bypass surgery in children with CHD. Pulmonary vasodilator therapies

A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD Read More »

The Clinical and Cost Utility of Cardiac Catheterizations in Infants with Bronchopulmonary Dysplasia

Emily L. Yang, Philip T. Levy, Paul J. Critser, Dmitry Dukhovny, Patrick D. EversOregon Health and Sciences University. Harvard Medical School and Boston Children’s Hospital. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center.United States Journal of PediatricsJ Pediatr 2022; 246: 56-63DOI: 10.1016/j.jpeds.2022.04.009

The Clinical and Cost Utility of Cardiac Catheterizations in Infants with Bronchopulmonary Dysplasia Read More »

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study

Anouk Pels, Wes Onland, Rolf M. F. Berger, Arno F. J. van Heijst, Enrico Lopriore, Irwin K. M. Reiss, Jacqueline Limpens, Sanne J. Gordijn, Wessel GanzevoortUniversity of Amsterdam and Emma Children’s Hospital. University of Groningen, University Medical Center Groningen and Beatrix Children’s Hospital. Radboud University Medical Center and Amalia Children’s Hospital. Leiden University Medical Center. Erasmus University Medical Center. Netherlands European Journal of PediatricsEur J Pediatr 2022; 181: 1709-1718DOI: 10.1007/s00431-021-04355-x AbstractThe aim was

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study Read More »

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M. Pierce, Min H. Zhang, Baldvin Jonsson, Dinu Iorga, Narayan Cheruvu, Cecile C. Balagtas, Robin H. SteinhornGreat Ormond Street Hospital for Children. Pfizer Inc. Karolinska Institute and University Hospital. Rady Children’s Hospital and University of California San Diego.United States Journal of PediatricsJ Pediatr 2021; 237: 154-161DOI: 10.1016/j.jpeds.2021.05.051 AbstractObjective: To investigate the efficacy and safety of sildenafil

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial Read More »

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension

Shinichi Takatsuki, Tomotaka Nakayama, Yurika Shimizu, Reiko Kawai, Hiroyuki MatsuuraToho University Omori Medical Center. Kochi Medical School Hospital.Japan Cardiology in the YoungCardiol Young 2023; 33: 196-200DOI: 10.1017/S1047951122000415 AbstractObjective: This study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.Methods: This retrospective cohort study included clinical

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension Read More »

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy

Regan E. Geisinger, Amy H. Stanford, Brady Thomas, Steven H. Abman, Patrick J. McNammaraUniversity of Iowa. University of Colorado.United States Journal of PediatricsJ Pediatr 2022; DOI: 10.1016/j.jpeds.2022.11.026 AbstractThe effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10),

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy Read More »

Scroll to Top